Peijie Lv1, Jie Liu1, Xiaopeng Yan1, Yaru Chai1, Yan Chen1, Jianbo Gao2, Yuanwei Pan1, Shuai Li1, Hua Guo1, Yue Zhou1. 1. The Department of Radiology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jianshe Road, Zhengzhou, Henan Province, China, 450052. 2. The Department of Radiology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jianshe Road, Zhengzhou, Henan Province, China, 450052. jianbogao0307@163.com.
Abstract
PURPOSE: The aim of this study was to evaluate the value of computed tomography (CT) spectral imaging in assessing the therapeutic efficacy of a vascular endothelial growth factor (VEGF) receptor inhibitor AG-013736 in rabbit VX2 liver tumours. METHODS: Twenty-three VX2 liver tumour-bearing rabbits were scanned with CT in spectral imaging mode during the arterial phase (AP) and portal phase (PP). The iodine concentrations(ICs)of tumours normalized to aorta (nICs) at different time points (baseline, 2, 4, 7, 10, and 14 days after treatment) were compared within the treated group (n = 17) as well as between the control (n = 6) and treated groups. Correlations between the tumour size, necrotic fraction (NF), microvessel density (MVD), and nICs were analysed. RESULTS: The change of nICs relative to baseline in the treated group was lower compared to the control group. A greater decrease in the nIC of a tumour at 2 days was positively correlated with a smaller increase in tumour size at 14 days (P < 0.05 for both). The tumour nIC values in AP and PP had correlations with MVD (r = 0.71 and 0.52) and NF (r = -0.54 and -0.51) (P < 0.05 for all). CONCLUSIONS: CT spectral imaging allows for the evaluation and early prediction of tumour response to AG-013736. KEY POINTS: • AG-013736 treatment response was evaluated by CT in a rabbit tumour model. • CT spectral imaging allows for the early treatment monitoring of targeted anti-tumour therapies. • Spectral CT findings correlated with vascular changes after anti-tumour therapies. • Spectral CT is a promising method for assessing clinical treatment response.
PURPOSE: The aim of this study was to evaluate the value of computed tomography (CT) spectral imaging in assessing the therapeutic efficacy of a vascular endothelial growth factor (VEGF) receptor inhibitor AG-013736 in rabbit VX2 liver tumours. METHODS: Twenty-three VX2 liver tumour-bearing rabbits were scanned with CT in spectral imaging mode during the arterial phase (AP) and portal phase (PP). The iodine concentrations(ICs)of tumours normalized to aorta (nICs) at different time points (baseline, 2, 4, 7, 10, and 14 days after treatment) were compared within the treated group (n = 17) as well as between the control (n = 6) and treated groups. Correlations between the tumour size, necrotic fraction (NF), microvessel density (MVD), and nICs were analysed. RESULTS: The change of nICs relative to baseline in the treated group was lower compared to the control group. A greater decrease in the nIC of a tumour at 2 days was positively correlated with a smaller increase in tumour size at 14 days (P < 0.05 for both). The tumour nIC values in AP and PP had correlations with MVD (r = 0.71 and 0.52) and NF (r = -0.54 and -0.51) (P < 0.05 for all). CONCLUSIONS: CT spectral imaging allows for the evaluation and early prediction of tumour response to AG-013736. KEY POINTS: • AG-013736 treatment response was evaluated by CT in a rabbit tumour model. • CT spectral imaging allows for the early treatment monitoring of targeted anti-tumour therapies. • Spectral CT findings correlated with vascular changes after anti-tumour therapies. • Spectral CT is a promising method for assessing clinical treatment response.
Authors: Yang Guo; Yue Zhang; Ning Jin; Rachel Klein; Jodi Nicolai; Robert J Lewandowski; Robert K Ryu; Reed A Omary; Andrew C Larson Journal: Invest Radiol Date: 2012-02 Impact factor: 6.016
Authors: Harriet C Thoeny; Frederik De Keyzer; Feng Chen; Vincent Vandecaveye; Erik K Verbeken; Bisan Ahmed; Xihe Sun; Yicheng Ni; Hilde Bosmans; Robert Hermans; Allan van Oosterom; Guy Marchal; Willy Landuyt Journal: Neoplasia Date: 2005-08 Impact factor: 5.715
Authors: G Sersa; T Jarm; T Kotnik; A Coer; M Podkrajsek; M Sentjurc; D Miklavcic; M Kadivec; S Kranjc; A Secerov; M Cemazar Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: K Hellbach; A Sterzik; W Sommer; M Karpitschka; N Hummel; J Casuscelli; M Ingrisch; M Schlemmer; A Graser; Michael Staehler Journal: Eur Radiol Date: 2016-09-27 Impact factor: 5.315